Cargando…

Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer

PURPOSE: Recent retrospective data suggest that brachytherapy (BT) boost may confer a cancer-specific survival benefit in radiation-managed high-risk prostate cancer. We sought to determine whether this survival benefit would extend to the recently defined favorable high-risk subgroup of prostate ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muralidhar, Vinayak, Xiang, Michael, Orio, Peter F., Martin, Neil E., Beard, Clair J., Feng, Felix Y., Hoffman, Karen E., Nguyen, Paul L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2016
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4793071/ https://www.ncbi.nlm.nih.gov/pubmed/26985191 http://dx.doi.org/10.5114/jcb.2016.58080

Ejemplares similares

Dose outside of the prostate is associated with improved outcomes for high-risk prostate cancer patients treated with brachytherapy boost
por: Shortall, Jane, et al.
Publicado: (2023)

MRS-guided HDR brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer
por: Kazi, Aleksandra, et al.
Publicado: (2010)

High-dose-rate brachytherapy boost for prostate cancer: rationale and technique
por: Morton, Gerard C.
Publicado: (2014)

HDR Brachytherapy in the Management of High-Risk Prostate Cancer
por: Masson, Susan, et al.
Publicado: (2012)

Stratification of brachytherapy-treated intermediate-risk prostate cancer patients into favorable and unfavorable cohorts
por: Merrick, Gregory S., et al.
Publicado: (2015)

Corrigendum to “HDR Brachytherapy in the Management of High-Risk Prostate Cancer”
por: Masson, Susan, et al.
Publicado: (2016)

Predicting toxicity caused by high-dose-rate brachytherapy single boost for prostate cancer
por: Olsén, Johan Staby, et al.
Publicado: (2022)

Unexpected lower biochemical control of high-dose-rate brachytherapy boost than low-dose-rate brachytherapy boost for clinically localized prostate cancer
por: Yamazaki, Hideya, et al.
Publicado: (2020)

High-dose-rate brachytherapy boost for elderly patients with intermediate to high-risk prostate cancer: 5-year clinical outcome of the PROSTAGE cohort
por: Marotte, Delphine, et al.
Publicado: (2022)

MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer
por: Ménard, Cynthia, et al.
Publicado: (2022)

Response to ‘Unexpected lower biochemical control of high-dose-rate brachytherapy boost than low-dose-rate brachytherapy boost for clinically localized prostate cancer’
por: Slevin, Finbar, et al.
Publicado: (2020)

A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate
por: Fischer-Valuck, Benjamin W., et al.
Publicado: (2019)

A comparison between high dose rate brachytherapy and stereotactic body radiotherapy boost after elective pelvic irradiation for high and very high-risk prostate cancer
por: Novikov, Sergey Nikolaevich, et al.
Publicado: (2022)

Natural History of Untreated Prostate Specific Antigen Radiorecurrent Prostate Cancer in Men with Favorable Prognostic Indicators
por: Martin, Neil E., et al.
Publicado: (2014)

Obstructive urination problems after high-dose-rate brachytherapy boost treatment for prostate cancer are avoidable
por: Kragelj, Borut
Publicado: (2016)

Corrigendum: MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer
por: Ménard, Cynthia, et al.
Publicado: (2022)

Role of Brachytherapy Boost in Clinically Localized Intermediate and High-Risk Prostate Cancer: Lack of Benefit in Patients with Very High-Risk Factors T3b–4 and/or Gleason 9–10
por: Yamazaki, Hideya, et al.
Publicado: (2022)

Interstitial high-dose rate brachytherapy as boost for anal canal cancer
por: Falk, Alexander Tuan, et al.
Publicado: (2014)

Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy
por: Lacy, John M., et al.
Publicado: (2016)

Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

Prostate cancer boost using high-dose-rate brachytherapy: early toxicity analysis of 3 different fractionation schemes
por: Hijazi, Hussam, et al.
Publicado: (2013)

High-dose-rate brachytherapy delivered in two fractions as monotherapy for low-risk prostate cancer
por: Cendales, Ricardo, et al.
Publicado: (2015)

High dose-rate brachytherapy in the treatment of prostate cancer
por: Mendez, Lucas C., et al.
Publicado: (2018)

A comparative study of high-dose-rate brachytherapy boost combined with external beam radiation therapy versus external beam radiation therapy alone for high-risk prostate cancer
por: Oshikane, Tomoya, et al.
Publicado: (2021)

Utilization of prostate brachytherapy for low risk prostate cancer: Is the decline overstated?
por: Safdieh, Joseph, et al.
Publicado: (2016)

Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy
por: Yamazaki, Hideya, et al.
Publicado: (2021)

After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer
por: Nakamura, Satoshi, et al.
Publicado: (2016)

Interstitial high-dose-rate brachytherapy as a boost in synchronous prostate and rectal cancer treatment: case report and literature review
por: Konat-Bąska, Katarzyna, et al.
Publicado: (2020)

Prostate cancer-specific death in brachytherapy treated high-risk patients stratified by pre-treatment PSA
por: Merrick, Gregory S., et al.
Publicado: (2017)

Ten‐step method of high‐dose LDR (125)I brachytherapy for intermediate‐risk prostate cancer
por: Okamoto, Keisei
Publicado: (2021)

Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer
por: Anwar, Mekhail, et al.
Publicado: (2016)

Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2016)

Low-/high-dose-rate brachytherapy boost in patients with intermediate-risk prostate cancer treated with radiotherapy: long-term results from a single institution team experience
por: Villalba, Silvia Rodríguez, et al.
Publicado: (2021)

High biologically effective dose radiation therapy using brachytherapy in combination with external beam radiotherapy for high-risk prostate cancer
por: Okamoto, Keisei, et al.
Publicado: (2017)

Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: A high-volume cancer center experience
por: Kamran, Sophia C., et al.
Publicado: (2017)

Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer
por: Ohashi, Toshio, et al.
Publicado: (2014)

Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in high‐risk localized prostate cancer
por: Yin, Ming, et al.
Publicado: (2019)

Contemporary approach to active surveillance for favorable risk prostate cancer
por: Klotz, Laurence
Publicado: (2019)

Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer
por: Loeb, Stacy, et al.
Publicado: (2017)

Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer
por: Kunogi, Hiroaki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f0od0f47vb25v8pfsqsn99q986